Hui Xu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Hui Xu has a total of 126 co-authors. Here are the top co-authors by number of shared publications:
- Liang-Hu Qu
MOE Key Laboratory of Gene Function and Regulation, State Key Laboratory of Biocontrol, School of Life Sciences, Sun Yat-sen University, Guangzhou, China
16 shared publications - Hui Zhou
State Key Laboratory of Biocontrol and Key Laboratory of Gene Engineering of the Ministry of Education, School of Life Sciences, Sun Yat-sen University, Guangzhou 510275, People's Republic of China
9 shared publications - Christian S. Hinrichs
Rutgers Cancer Institute, New Brunswick, NJ, USA
8 shared publications - Jian-Hua Yang
Key Laboratory of Gene Engineering of the Ministry of Education, Sun Yat-sen University, Guangzhou, China
8 shared publications - Richard A. Morgan
Surgery Branch, National Cancer Institute, Clinical Research Center, Bethesda, MD 20892
8 shared publications - Soldano Ferrone
Department of Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02115, USA
8 shared publications
Latest Publications
- Open Access
A Multicenter Retrospective Study of HbH in China Including 1421 Patients Over a 12‐Year Timespan
Background: Hemoglobin H (HbH) disease is a relatively common genetic disorder worldwide. However, the lack of long‐term follow‐up studies involving large patient cohorts has limited our understanding of its clinical features, disease progression, and outcomes.Methods: We conducted a retrospective study of 1421 patients diagnosed with HbH disease who were admitted to six hospitals in the Guangxi Zhuang Autonomous Region, China, between 2010 and 2022. We analyzed hemoglobin levels and their association with different genotypes and ages. Key hematological parameters, serum ferritin levels, and visit frequency were compared between patients with HbH‐constant spring (HbH‐CS) and those with deletional HbH. Additionally, we assessed the survival status of 117 patients over 30 years of age and examined complications and causes of death in four patients who died during the study period.Results: In the cohort, 73.0% of patients had HbH‐CS, while 24.2% had deletional HbH. Patients with HbH‐CS exhibited a significantly younger average age, lower mean and minimum hemoglobin (Hb) levels, and higher visit frequencies and serum ferritin levels compared with those with deletional HbH. Iron overload was common in HbH‐CS patients, with a mean serum ferritin level of 1284 ± 1231 ng/mL (measured in 671 patients). Among the four deceased patients (aged 44.8 to 68.5 years), at least two deaths were attributed to severe anemia and related complications.Conclusion: This study provides valuable insights into the natural history, clinical progression, and long‐term outcomes of HbH disease in a large patient cohort over the past decade. It highlights key differences between HbH‐CS and deletional HbH, particularly in terms of disease severity, iron overload, and survival outcomes.Clinical Trail Registration: The authors have confirmed clinical trial registration is not needed for this submission.
Open AccessA Multicenter Retrospective Study of HbH in China Including 1421 Patients Over a 12‐Year Timespan
Background: Hemoglobin H (HbH) disease is a relatively common genetic disorder worldwide. However, the lack of long‐term follow‐up studies involving large patient cohorts has limited our understanding of its clinical features, disease progression, and outcomes.Methods: We conducted a retrospective study of 1421 patients diagnosed with HbH disease who were admitted to six hospitals in the Guangxi Zhuang Autonomous Region, China, between 2010 and 2022. We analyzed hemoglobin levels and their association with different genotypes and ages. Key hematological parameters, serum ferritin levels, and visit frequency were compared between patients with HbH‐constant spring (HbH‐CS) and those with deletional HbH. Additionally, we assessed the survival status of 117 patients over 30 years of age and examined complications and causes of death in four patients who died during the study period.Results: In the cohort, 73.0% of patients had HbH‐CS, while 24.2% had deletional HbH. Patients with HbH‐CS exhibited a significantly younger average age, lower mean and minimum hemoglobin (Hb) levels, and higher visit frequencies and serum ferritin levels compared with those with deletional HbH. Iron overload was common in HbH‐CS patients, with a mean serum ferritin level of 1284 ± 1231 ng/mL (measured in 671 patients). Among the four deceased patients (aged 44.8 to 68.5 years), at least two deaths were attributed to severe anemia and related complications.Conclusion: This study provides valuable insights into the natural history, clinical progression, and long‐term outcomes of HbH disease in a large patient cohort over the past decade. It highlights key differences between HbH‐CS and deletional HbH, particularly in terms of disease severity, iron overload, and survival outcomes.Clinical Trail Registration: The authors have confirmed clinical trial registration is not needed for this submission.
- Open Access
- 4 December 2023
- Published by Springer Nature in Journal of Translational Medicine
- Vol. 21 (1) , 1-18
Cucurbitacin E reduces IL-1β-induced inflammation and cartilage degeneration by inhibiting the PI3K/Akt pathway in osteoarthritic chondrocytes
Background: Osteoarthritis is a degenerative joint disease. Cartilage degeneration is the earliest and most important pathological change in osteoarthritis, and persistent inflammation is one of the driving factors of cartilage degeneration. Cucurbitacin E, an isolated compound in the Cucurbitacin family, has been shown to have anti-inflammatory effects, but its role and mechanism in osteoarthritic chondrocytes are unclear. Methods: For in vitro experiments, human chondrocytes were stimulated with IL-1β, and the expression of inflammatory genes was measured by Western blotting and qPCR. The expression of extracellular matrix proteins was evaluated by immunofluorescence staining, Western blotting and saffron staining. Differences in gene expression between cartilage from osteoarthritis patients and normal cartilage were analysed by bioinformatics methods, and the relationship between Cucurbitacin E and its target was analysed by a cellular thermal shift assay, molecular docking analysis and molecular dynamics simulation. For in vivo experiments, knee osteoarthritis was induced by DMM in C57BL/6 mouse knee joints, and the effect of Cucurbitacin E on knee joint degeneration was evaluated. Results: The in vitro experiments confirmed that Cucurbitacin E effectively inhibited the production of the inflammatory cytokine interleukin-1β(IL-1β) and cyclooxygenase-2 (COX-2) by IL-1β-stimulated chondrocytes and alleviates extracellular matrix degradation. The in vivo experiments demonstrated that Cucurbitacin E had a protective effect on the knee cartilage of C57BL/6 mice with medial meniscal instability in the osteoarthritis model. Mechanistically, bioinformatic analysis of the GSE114007 and GSE117999 datasets showed that the PI3K/AKT pathway was highly activated in osteoarthritis. Immunohistochemical analysis of PI3K/Akt signalling pathway proteins in pathological slices of human cartilage showed that the level of p-PI3K in patients with osteoarthritis was higher than that in the normal group. PI3K/Akt were upregulated in IL-1β-stimulated chondrocytes, and Cucurbitacin E intervention reversed this phenomenon. The cellular thermal shift assay, molecular docking analysis and molecular dynamics experiment showed that Cucurbitacin E had a strong binding affinity for the inhibitory target PI3K. SC79 activated Akt phosphorylation and reversed the effect of Cucurbitacin E on IL-1β-induced chondrocyte degeneration, demonstrating that Cucurbitacin E inhibits IL-1β-induced chondrocyte inflammation and degeneration by inhibiting the PI3K/AKT pathway. Conclusion: Cucurbitacin E inhibits the activation of the PI3K/AKT pathway, thereby alleviating the progression of OA. In summary, we believe that Cucurbitacin E is a potential drug for the treatment of OA.
- 4 December 2023
- Published by Springer Nature in Journal of Translational Medicine
- Vol. 21 (1) , 1-18
Open AccessCucurbitacin E reduces IL-1β-induced inflammation and cartilage degeneration by inhibiting the PI3K/Akt pathway in osteoarthritic chondrocytes
Background: Osteoarthritis is a degenerative joint disease. Cartilage degeneration is the earliest and most important pathological change in osteoarthritis, and persistent inflammation is one of the driving factors of cartilage degeneration. Cucurbitacin E, an isolated compound in the Cucurbitacin family, has been shown to have anti-inflammatory effects, but its role and mechanism in osteoarthritic chondrocytes are unclear. Methods: For in vitro experiments, human chondrocytes were stimulated with IL-1β, and the expression of inflammatory genes was measured by Western blotting and qPCR. The expression of extracellular matrix proteins was evaluated by immunofluorescence staining, Western blotting and saffron staining. Differences in gene expression between cartilage from osteoarthritis patients and normal cartilage were analysed by bioinformatics methods, and the relationship between Cucurbitacin E and its target was analysed by a cellular thermal shift assay, molecular docking analysis and molecular dynamics simulation. For in vivo experiments, knee osteoarthritis was induced by DMM in C57BL/6 mouse knee joints, and the effect of Cucurbitacin E on knee joint degeneration was evaluated. Results: The in vitro experiments confirmed that Cucurbitacin E effectively inhibited the production of the inflammatory cytokine interleukin-1β(IL-1β) and cyclooxygenase-2 (COX-2) by IL-1β-stimulated chondrocytes and alleviates extracellular matrix degradation. The in vivo experiments demonstrated that Cucurbitacin E had a protective effect on the knee cartilage of C57BL/6 mice with medial meniscal instability in the osteoarthritis model. Mechanistically, bioinformatic analysis of the GSE114007 and GSE117999 datasets showed that the PI3K/AKT pathway was highly activated in osteoarthritis. Immunohistochemical analysis of PI3K/Akt signalling pathway proteins in pathological slices of human cartilage showed that the level of p-PI3K in patients with osteoarthritis was higher than that in the normal group. PI3K/Akt were upregulated in IL-1β-stimulated chondrocytes, and Cucurbitacin E intervention reversed this phenomenon. The cellular thermal shift assay, molecular docking analysis and molecular dynamics experiment showed that Cucurbitacin E had a strong binding affinity for the inhibitory target PI3K. SC79 activated Akt phosphorylation and reversed the effect of Cucurbitacin E on IL-1β-induced chondrocyte degeneration, demonstrating that Cucurbitacin E inhibits IL-1β-induced chondrocyte inflammation and degeneration by inhibiting the PI3K/AKT pathway. Conclusion: Cucurbitacin E inhibits the activation of the PI3K/AKT pathway, thereby alleviating the progression of OA. In summary, we believe that Cucurbitacin E is a potential drug for the treatment of OA.
- Open Access
- 16 November 2023
- Published by Elsevier in Ecotoxicology and Environmental Safety
- Vol. 268, 115684
Effect of environmental level of methomyl on hatching, morphology, immunity and development related genes expression in zebrafish (Danio rerio) embryo
- 16 November 2023
- Published by Elsevier in Ecotoxicology and Environmental Safety
- Vol. 268, 115684
Open AccessEffect of environmental level of methomyl on hatching, morphology, immunity and development related genes expression in zebrafish (Danio rerio) embryo
- Open Access
- 30 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 2 from A High Molecular Weight Melanoma-Associated Antigen–Specific Chimeric Antigen Receptor Redirects Lymphocytes to Target Human Melanomas
Supplementary Figure 2 from A High Molecular Weight Melanoma-Associated Antigen–Specific Chimeric Antigen Receptor Redirects Lymphocytes to Target Human Melanomas
- 30 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 2 from A High Molecular Weight Melanoma-Associated Antigen–Specific Chimeric Antigen Receptor Redirects Lymphocytes to Target Human Melanomas
Supplementary Figure 2 from A High Molecular Weight Melanoma-Associated Antigen–Specific Chimeric Antigen Receptor Redirects Lymphocytes to Target Human Melanomas
- Open Access
- 30 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 3 from A High Molecular Weight Melanoma-Associated Antigen–Specific Chimeric Antigen Receptor Redirects Lymphocytes to Target Human Melanomas
Supplementary Figure 3 from A High Molecular Weight Melanoma-Associated Antigen–Specific Chimeric Antigen Receptor Redirects Lymphocytes to Target Human Melanomas
- 30 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 3 from A High Molecular Weight Melanoma-Associated Antigen–Specific Chimeric Antigen Receptor Redirects Lymphocytes to Target Human Melanomas
Supplementary Figure 3 from A High Molecular Weight Melanoma-Associated Antigen–Specific Chimeric Antigen Receptor Redirects Lymphocytes to Target Human Melanomas
- Open Access
- 30 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 5 from A High Molecular Weight Melanoma-Associated Antigen–Specific Chimeric Antigen Receptor Redirects Lymphocytes to Target Human Melanomas
Supplementary Figure 5 from A High Molecular Weight Melanoma-Associated Antigen–Specific Chimeric Antigen Receptor Redirects Lymphocytes to Target Human Melanomas
- 30 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 5 from A High Molecular Weight Melanoma-Associated Antigen–Specific Chimeric Antigen Receptor Redirects Lymphocytes to Target Human Melanomas
Supplementary Figure 5 from A High Molecular Weight Melanoma-Associated Antigen–Specific Chimeric Antigen Receptor Redirects Lymphocytes to Target Human Melanomas
- Open Access
- 30 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 5 from A High Molecular Weight Melanoma-Associated Antigen–Specific Chimeric Antigen Receptor Redirects Lymphocytes to Target Human Melanomas
Supplementary Figure 5 from A High Molecular Weight Melanoma-Associated Antigen–Specific Chimeric Antigen Receptor Redirects Lymphocytes to Target Human Melanomas
- 30 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 5 from A High Molecular Weight Melanoma-Associated Antigen–Specific Chimeric Antigen Receptor Redirects Lymphocytes to Target Human Melanomas
Supplementary Figure 5 from A High Molecular Weight Melanoma-Associated Antigen–Specific Chimeric Antigen Receptor Redirects Lymphocytes to Target Human Melanomas
- Open Access
- 30 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 2 from A High Molecular Weight Melanoma-Associated Antigen–Specific Chimeric Antigen Receptor Redirects Lymphocytes to Target Human Melanomas
Supplementary Figure 2 from A High Molecular Weight Melanoma-Associated Antigen–Specific Chimeric Antigen Receptor Redirects Lymphocytes to Target Human Melanomas
- 30 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 2 from A High Molecular Weight Melanoma-Associated Antigen–Specific Chimeric Antigen Receptor Redirects Lymphocytes to Target Human Melanomas
Supplementary Figure 2 from A High Molecular Weight Melanoma-Associated Antigen–Specific Chimeric Antigen Receptor Redirects Lymphocytes to Target Human Melanomas
- Open Access
- 30 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 4 from A High Molecular Weight Melanoma-Associated Antigen–Specific Chimeric Antigen Receptor Redirects Lymphocytes to Target Human Melanomas
Supplementary Figure 4 from A High Molecular Weight Melanoma-Associated Antigen–Specific Chimeric Antigen Receptor Redirects Lymphocytes to Target Human Melanomas
- 30 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 4 from A High Molecular Weight Melanoma-Associated Antigen–Specific Chimeric Antigen Receptor Redirects Lymphocytes to Target Human Melanomas
Supplementary Figure 4 from A High Molecular Weight Melanoma-Associated Antigen–Specific Chimeric Antigen Receptor Redirects Lymphocytes to Target Human Melanomas
- Open Access
- 30 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 6 from A High Molecular Weight Melanoma-Associated Antigen–Specific Chimeric Antigen Receptor Redirects Lymphocytes to Target Human Melanomas
Supplementary Figure 6 from A High Molecular Weight Melanoma-Associated Antigen–Specific Chimeric Antigen Receptor Redirects Lymphocytes to Target Human Melanomas
- 30 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 6 from A High Molecular Weight Melanoma-Associated Antigen–Specific Chimeric Antigen Receptor Redirects Lymphocytes to Target Human Melanomas
Supplementary Figure 6 from A High Molecular Weight Melanoma-Associated Antigen–Specific Chimeric Antigen Receptor Redirects Lymphocytes to Target Human Melanomas